Atul Ltd

Chemicals

Atul Ltd

Chemicals

Milars Portfolio

CMP
Rs. 7582.75
Rating:
Buy
April 15, 2021

Stock Info

BSE
500027
NSE
ATUL
Bloomberg
ATLP:IN
Reuters
ATLP.BO
Sector
Chemicals
Face Value (Rs)
10
Equity Capital (Rs cr)
29.7
Mkt Cap (Rs cr)
22407.75
52w H/L (Rs)
8086.00 - 4150.00
Avg Daily Vol (BSE+NSE)
44,047

Shareholding Pattern

(as on 31-Mar)
%
Promoter
44.93
FIIs
9.48
DIIs
23.11
Public & Others
22.48
Source: Ace equity, StockAxis Research

Price performance

Return (%)
1m
3m
12m
Absolute
11.67
14.84
79.63
Sensex
-3.16
-0.47
60.65
Source: Ace equity, StockAxis Research

Indexed Stock Performance

Atul Ltd Sensex
Atul Ltd
Source: Ace equity, StockAxis Research

Chemistry at work

Profile
Atul Ltd, one of the oldest and largest integrated chemical manufacturers in India is in the business of Life science chemicals (LCS) & Performance & other chemicals (POC), catering to the requirement of diversified industries like textile, paints & coatings, adhesives, dyestuff, agriculture, fragrance & flavours, cosmetic, personal care, tyre, paper, plastic, pharmaceutical, aerospace, composites, construction, glass, etc. Its life science business consists of three sub segments, namely, crop protection, Pharmaceuticals & Intermediates & Aromatics - I. Its POC business consists of four sub segments, namely, Aromatics-II, Bulk chemicals & intermediates, colors & Polymers. As on FY20, LCS & POC contributed 31% & 69% of the total revenue respectively. The company has 400 formulations & 900 products in FY20 across all segments and is focussed in adding more value-added products to the portfolio. The company has ~4,000 customers across 90 countries. The company works with 2,250 distributors & operates through a network of 38,000 retail outlets in India.

Consolidated Financial Statements

Rs in Cr Net Sales EBITDA EBITDAM PAT EPS ROE P/E EV/EBITDA
FY18 3295.77 505.19 15.33% 276.48 93.22 12.32% 28.04 15.27
FY19 4037.81 766.78 18.99% 432.23 145.73 15.97% 24.61 13.60
FY20 4093.06 902.01 22.04% 666.46 224.70 21.12% 17.75 12.47
FY21E 3683.75 909.89 24.70% 637.51 214.79 17.16% 37.21 24.65
FY22E 4604.69 1059.08 23.00% 753.60 253.91 17.21% 31.44 20.61
FY23E 5341.44 1239.21 23.20% 902.21 302.30 18.78% 26.23 17.12

Investment Rationale

Strong growth from multiple JV’s
Joint venture (JV) with Anaven
The objective of this JV is to produce mono chloro acetic acid (MCA) which will use chlorine and hydrogen manufactured at Atul taking advantage of Atul’s existing infrastructure and Anaven’s leading hydrogenation technology. MCA is used in agrochemicals, adhesives, pharmaceuticals, surfactants, thermo stabilisers and cosmetics in addition to being a key raw material for 2,4D. The plant has capacity to produce 32,000 tonnes per year with expansion potential of upto 60,000 tonnes per year. The main goal is to meet the entire demand of MCA in India.

Joint venture (JV) with Rudolf
This is one of the fastest growing JV’s of Atul with a CAGR of 38% from FY12-20. This JV offers a complete range of textile products in Indian market and contributes 2% of the total company revenue.

Strong performance from key subsidiary
Atul Bioscience is wholly owned subsidiary of Atul Ltd. The business of this subsidiary is to manufacture and market API’s and their intermediaries clocking 3% of total company revenue. The facility at Ambernath is expected to generate revenue north of Rs 270 crore with the plan to ramp it up to 450-500 crore by planning a capex of 25-35 crore at the same site.

Strong R&D focus
Atul’s R&D expense has increased from 0.54% of sales in FY10 to 0.82% of sales in FY20. However, it still remains below industry average of ~2%. We believe Atul’s R&D team is more focussed on process improvement instead of product development. With the help of R&D, company increased yield of 18 products, decreased consumption of raw materials in five products, decreased consumption charge of two solvents, recovered ten products from pollutants and introduced 40 new products and formulation. The company is investing further in people and equipment so as to strengthen its R&D and thereby enhance its capability.

Key Product Portfolio

Segment Life Science Chemical Performance & Others Chemicals
Sub Segment Crop Protection Pharmaceuticals & Intermediates Aromatics -II Bulk chemical & Intermediates Colors Polymers
FY20 Revenues (cr) 703 462 694 286 626 1,041
Contribution of the total revenue (%) 18% 12% 18% 8% 16% 27%
Product Group Herbicides, Insecticides, Fungicides API intermediates, Active Pharmaceutical Ingredients, Others Intermediates, Perfumery, Others Bulk chemicals, Adhesion promoters, Others Dyestuffs, Pigments, Dye-intermediates, Textile chemicals, Others Epoxy resins, curing agents, Reactive diluents, Sulfones, Protective paints and Adhesives based on Epoxy, Synthetic rubber, Polyurethane, Cyanoacrylate, PVC and PVA
Products & Formulation Products -20
Formulations -70
Products -76 Products -31 Products -23 Products -620 Products - 96
Formulation – 300
Key Products 2,4-D, Indoxacarb and Isoprothiolane For Active pharmaceutical ingredients - Dapsone, fluconazole and metoprolol salts.
For API intermediates. - carbonates, chloroformates and amino acid derivatives.
para Cresol and its downstream products like Para
Anisyl Alcohol,para Anisic aldehyde and para Cresidine.
Resorcinol, Resorcinol formaldehyde resin and 1,3–Cyclohexanedione Pigment Red 168, Sulphur Black 1 and Vat Green 1 Lapox, Epoxy Resins, Hardeners
Market Share of key products 2,4-D- 16% (Global)
Indoxacarb - 7% (Global)
Dapsone -50% (Global) Para Cresol -42% (Global) Resorcinol - Significant market share (only manufacturer in India) NA Epoxy: 32% (India)
Key User Industries Agriculture industry Used in Pharmaceutical
industry for various therapeutic
categories, such as anti-depressant,
anti-diabetic, anti-infective, anti-fungal,
anti-retroviral and cardiovascular
Fragrance and Personal Care industries Cosmetic, Dyestuff, Pharmaceutical
and Tyre industries.
Textile, Paint and Coatings and Paper industries Aerospace, Automobile, Composites, Construction, Defence, Electrical and Electronics, Footwear, Paint and Coatings, Paper, Sport and Leisure and Wind Energy industries

Industry Size of key products

Segment Sub Segment Industry Size
Life Science Chemical Crop Protection Global market of crop protection - US$ 59.5 bn, growing at 2.4% P.a
Pharmaceuticals & Intermediates Global market of API - US$160bn
Performance & Others Chemicals Aromatics -II Global market of Para Cresol - 66,300MT, growing at 2%.
Global Size of fragrance industry -US$ 13.5bn, growing at 4%.
Global Size of Personal Care Industry -US$ 431bn of which
personal care ingredients segment is
US$ 25 bn and is growing at about 4%
Bulk chemical & Intermediates Global market of Resorcino -US$ 564 mn, growing at 2.5%.
Global market of Tyre Industry - US$ 237bn, growing at 3.7%
Colors Global size of Dyestuff industry is estimated at US$ 6.1 bn and is growing at ~2%.
Global market of pigment is ~5bn and is expected to grow at 4%.
Polymers Global market for epoxy resins and curing agents is estimated at US$ 7.6 bn and is growing at about 2% and Indian market is estimated at US$ 285 mn and is growing at about 6%

Outlook & valuation

We believe the chemicals space would continue to grow driven by china plus one & import substitution theme resulting into sustainable earnings growth. We believe Atul is best poised to take the benefit as it is in leader in multiple products, has well-built infrastructure with lot of emphasis on environment which puts it at a significant advantage against most Indian players, backward integrated and focus on downstream products, established distribution network & strong balance sheet. At the price of 7,930, stock is trading at the PE of 26.23X on the basis of FY23E earnings.

Financial Statement

Profit & Loss statement

Yr End March (Rs Cr) 2018 2019 2020 2021E 2022E 2023E
Net Sales 3295.77 4037.81 4093.06 3683.75 4604.69 5341.44
Growth 16.30% 22.51% 1.37% -10.00% 25.00% 16.00%
Expenditure
Material Cost 1803.47 2106.08 1970.03 1694.53 2205.65 2563.89
Employee Cost 213.38 259.84 300.90 298.38 331.54 373.90
Other Expenses 773.73 905.11 920.12 780.96 1008.43 1164.43
EBITDA 505.19 766.78 902.01 909.89 1059.08 1239.21
Growth -0.84% 51.78% 17.64% 0.87% 16.40% 17.01%
EBITDA Margin 15.33% 18.99% 22.04% 24.70% 23.00% 23.20%
Depreciation & Amortization 110.38 118.91 130.21 148.10 165.20 181.70
EBIT 394.81 647.87 771.80 761.79 893.88 1057.51
EBIT Margin 11.98% 16.05% 18.86% 20.68% 19.41% 19.80%
Other Income 25.91 34.86 78.04 93.35 114.40 140.70
Interest & Finance Charges 12.74 7.41 9.40 9.85 7.85 5.85
Profit Before Tax - Before Exceptional 407.98 675.32 840.44 845.29 1000.43 1197.34
Profit Before Tax 407.98 675.32 840.44 845.29 1000.43 1197.34
Tax Expense 130.97 244.32 174.51 212.76 251.81 300.12
Effective Tax rate 32.10% 36.18% 20.76% 25.17% 25.17% 25.17%
Net Profit 277.01 431.00 665.93 632.53 748.62 897.23
Growth -13.08% 55.59% 54.51% -5.02% 18.35% 19.85%
Net Profit Margin 8.41% 10.67% 16.27% 17.17% 16.26% 16.80%
Consolidated Net Profit 276.48 432.23 666.46 637.51 753.60 902.21
Growth -14.39% 56.33% 54.19% -4.34% 18.21% 19.72%
Net Profit Margin after MI 8.39% 10.70% 16.28% 17.31% 16.37% 16.89%

Balance Sheet

Yr End March (Rs Cr) 2018 2019 2020 2021E 2022E 2023E
Share Capital 29.68 29.68 29.68 29.68 29.68 29.68
Total Reserves 2214.24 2676.03 3125.22 3686.23 4349.40 5143.94
Shareholders' Funds 2243.92 2705.71 3154.90 3715.91 4379.08 5173.62
Minority Interest 20.01 23.80 26.37 26.37 26.37 26.37
Non Current Liabilities
Long Term Burrowing - 43.14 86.58 78.08 58.08 38.08
Deferred Tax Assets / Liabilities 124.54 138.96 107.84 98.66 98.66 98.66
Long Term Provisions 17.84 19.13 20.06 20.06 20.06 20.06
Current Liabilities
Short Term Borrowings 15.91 9.32 10.39 10.39 10.39 10.39
Trade Payables 459.02 379.63 477.63 426.13 454.16 544.99
Other Current Liabilities 74.81 157.74 205.36 193.86 193.86 193.86
Short Term Provisions 122.42 281.62 251.24 251.24 251.24 251.24
Total Equity & Liabilities 3112.00 3794.53 4356.42 4836.75 5507.95 6373.32
Assets
Net Block 1035.56 1114.22 1121.66 1148.56 1158.36 1176.65
Non Current Investments 467.36 546.42 488.84 493.82 498.80 503.78
Long Term Loans & Advances 15.32 41.77 63.78 63.78 63.78 63.78
Current Assets
Currents Investments 5.70 208.81 651.69 651.69 651.69 651.69
Inventories 411.43 511.82 503.37 479.39 510.93 613.12
Sundry Debtors 723.40 698.47 719.73 681.80 726.66 871.99
Cash and Bank 49.39 54.50 35.37 545.72 1125.75 1720.33
Short Term Loans and Advances 104.04 252.74 214.24 214.24 214.24 214.24
Total Assets 3112.00 3794.53 4356.42 4836.75 5507.95 6373.32

Cash Flow Statement

Yr End March (Rs Cr) 2018 2019 2020 2021E 2022E 2023E
Profit After Tax 277.01 431.00 665.93 632.53 748.62 897.23
Depreciation 110.38 118.91 130.21 148.10 165.20 181.70
Others 15.67 12.15 81.55 - - -
Changes in Working Capital -59.43 -142.70 166.74 10.40 -48.36 -156.69
Cash From Operating Activities 355.71 403.58 881.38 791.03 865.46 922.24
Purchase of Fixed Assets -143.04 -208.35 -373.99 -175.00 -175.00 -200.00
Free Cash Flows 212.67 195.23 507.39 616.03 690.46 722.24
Others 12.91 -199.11 -412.24 - - -
Cash Flow from Investing Activities -130.13 -407.46 -785.66 -175.00 -175.00 -200.00
Increase / (Decrease) in Loan Funds -151.78 38.85 53.70 -20.00 -20.00 -20.00
Equity Dividend Paid -37.88 -41.04 -150.41 -76.50 -90.43 -107.67
Others -17.74 1.11 -10.88 - - -
Cash from Financing Activities -207.40 -1.08 -107.59 -96.50 -110.43 -127.67
Net Cash Inflow / Outflow 18.18 -4.96 -11.87 519.53 580.03 594.58
Opening Cash & Cash Equivalents 23.44 42.67 37.59 26.19 545.72 1125.75
Closing Cash & Cash Equivalent 42.67 37.59 26.19 545.72 1125.75 1720.33

Key Ratios

Yr End March 2018 2019 2020 2021E 2022E 2023E
Basic EPS 93.22 145.73 224.70 214.79 253.91 302.30
Diluted EPS 93.22 145.73 224.70 214.79 253.91 302.30
Cash EPS 130.43 185.82 268.60 264.69 309.57 363.52
DPS 12.00 15.00 27.50 25.78 30.47 36.28
Book value (Rs/share) 756.54 912.24 1063.68 1251.99 1475.43 1743.13
ROCE Post Tax 13.07% 17.37% 22.41% 18.14% 18.29% 18.55%
ROE 12.32% 15.97% 21.12% 17.16% 17.21% 18.78%
Inventory Days 46.00 41.73 45.26 45.00 45.00 45.00
Receivable Days 68.79 64.27 63.23 64.00 64.00 64.00
Payable Days 44.11 37.91 38.22 40.00 40.00 40.00
PE (x) 28.04 24.61 17.75 37.21 31.44 26.23
P/BV (x) 3.45 3.93 3.75 6.33 5.37 4.55
EV/EBITDA (x) 15.27 13.60 12.47 24.65 20.61 17.12
Dividend Yield 0.46% 0.42% 0.69% 0.33% 0.38% 0.46%
P/Sales (x) 2.35 2.63 2.89 6.39 5.11 4.41
Sales/Net FA (x) 3.19 3.76 3.66 3.25 3.99 4.58